EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA

Current therapy for glioblastoma (GBM) is incapacitating and limited by non-specific toxicity to the surrounding brain. We have developed an immunotherapeutic approach that selectively targets GBM by redirecting the patients’ own T cells towards the tumor in an antigen-specific manner using a bispec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Schaller, Teilo, Foster, Matthew, Spasojevic, Ivan, Gedeon, Patrick, Sanchez-Perez, Luis, Sampson, John
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Experimental Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847514/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.343
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller